BACKGROUND & AIMS: We investigated the expression of estrogen receptor (ER) alpha and beta subtypes in cholangiocytes of normal and bile duct-ligated (BDL) rats and evaluated the role and mechanisms of estrogens in the modulation of cholangiocyte proliferation. METHODS: ER-alpha and ER-beta were analyzed by immunohistochemistry, reverse-transcription polymerase chain reaction, and Western blotting in normal and BDL rats. The effects of the ER antagonists tamoxifen and ICI 182,780 on cholangiocyte proliferation were evaluated. RESULTS: Cholangiocytes expressed both ER-alpha and ER-beta subtypes, whereas hepatocytes expressed only ER-alpha. In association with a marked cholangiocyte proliferation and with enhanced estradiol serum levels, the immunoreactivity for ER-alpha involved a 3-fold higher percentage of cholangiocytes in 3-week BDL than in normal rats; immunoreactivity for ER-beta showed a 30-fold increase. Western blot analysis showed that during BDL, the total amount of ER-beta in cholangiocytes was markedly increased (5-fold), whereas that of ER-alpha decreased slightly (-25%). Treatment with tamoxifen or ICI 182,780 of 3-week BDL rats inhibited cholangiocyte proliferation and induced overexpression of Fas antigen and apoptosis in cholangiocytes. In vitro, 17 beta estradiol stimulated proliferation of cholangiocyte, an effect blocked to the same extent by tamoxifen or ICI 182,780. CONCLUSIONS: This study suggests that estrogens and their receptors play a role in the modulation of cholangiocyte proliferation.
BACKGROUND & AIMS: We investigated the expression of estrogen receptor (ER) alpha and beta subtypes in cholangiocytes of normal and bile duct-ligated (BDL) rats and evaluated the role and mechanisms of estrogens in the modulation of cholangiocyte proliferation. METHODS:ER-alpha and ER-beta were analyzed by immunohistochemistry, reverse-transcription polymerase chain reaction, and Western blotting in normal and BDL rats. The effects of the ER antagonists tamoxifen and ICI 182,780 on cholangiocyte proliferation were evaluated. RESULTS: Cholangiocytes expressed both ER-alpha and ER-beta subtypes, whereas hepatocytes expressed only ER-alpha. In association with a marked cholangiocyte proliferation and with enhanced estradiol serum levels, the immunoreactivity for ER-alpha involved a 3-fold higher percentage of cholangiocytes in 3-week BDL than in normal rats; immunoreactivity for ER-beta showed a 30-fold increase. Western blot analysis showed that during BDL, the total amount of ER-beta in cholangiocytes was markedly increased (5-fold), whereas that of ER-alpha decreased slightly (-25%). Treatment with tamoxifen or ICI 182,780 of 3-week BDL rats inhibited cholangiocyte proliferation and induced overexpression of Fas antigen and apoptosis in cholangiocytes. In vitro, 17 beta estradiol stimulated proliferation of cholangiocyte, an effect blocked to the same extent by tamoxifen or ICI 182,780. CONCLUSIONS: This study suggests that estrogens and their receptors play a role in the modulation of cholangiocyte proliferation.
Authors: Sue K Park; Gabriella Andreotti; Asif Rashid; Jinbo Chen; Philip S Rosenberg; Kai Yu; Jennifer Olsen; Yu-Tang Gao; Jie Deng; Lori C Sakoda; Mingdong Zhang; Ming-Chang Shen; Bing-Sheng Wang; Tian-Quan Han; Bai-He Zhang; Meredith Yeager; Stephen J Chanock; Ann W Hsing Journal: Carcinogenesis Date: 2010-02-19 Impact factor: 4.944
Authors: Angela C Cheung; Maria J Lorenzo Pisarello; Nicholas F LaRusso Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-07-15 Impact factor: 5.187
Authors: Domenico Alvaro; Paolo Onori; Gianfranco Alpini; Antonio Franchitto; Douglas M Jefferson; Alessia Torrice; Vincenzo Cardinale; Fabrizio Stefanelli; Maria Grazia Mancino; Mario Strazzabosco; Mario Angelico; Adolfo Attili; Eugenio Gaudio Journal: Am J Pathol Date: 2008-01-17 Impact factor: 4.307
Authors: Michele Barone; Eugenio Maiorano; Roberta Ladisa; Antonia Pece; Pasquale Berloco; Mario Strazzabosco; Maria Lucia Caruso; Anna Maria Valentini; Enzo Ierardi; Alfredo Di Leo; Antonio Francavilla Journal: Virchows Arch Date: 2004-04-08 Impact factor: 4.064
Authors: María L Ruiz; Juan P Rigalli; Agostina Arias; Silvina Villanueva; Claudia Banchio; Mary Vore; Aldo D Mottino; Viviana A Catania Journal: Drug Metab Dispos Date: 2012-10-17 Impact factor: 3.922